Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial
Vaccine Oct 19, 2017
Sirima SB, et al. - Safety and immunogenicity of Plasmodium falciparum Apical Membrane Antigen 1 Diversity Covering (PfAMA1-DiCo) candidate vaccine was tested among European and African adults who received AMA1-DiCo with either Alhydrogel or GLA-SE. Findings revealed that regardless of the adjuvant, AMA1-DiCo vaccine was safe and immunogenic, however, GLA-SE appeared more potent than Alhydrogel at inducing IgG responses.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries